Close

Trending

Why reshoring drug production means embracing continuous manufacturing

Clariness, DailyBreath partner to drive recruitment in asthma trials

J&J says it will stop selling all talc products next year

Cumulus’ gamified dry EEG system tops lab monitoring in trial

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

ADA 2017

San Diego Cityscape

Biotech vTv believes small molecule GLP-1 pill can take on big players

Richard Staines ADA 2017, Diabetes, Novo Nordisk, R&D, vTv Therapeutics 0 Comment

Pill could be effective in diabetes, with fewer GI effects.

X

Biotech vTv believes small molecule GLP-1 pill can take on big players

https://pharmaphorum.com/news/vtv-showcases-glp-1-pill-looks-funds/

SanDiego2

Healthcare/ News

Oral insulin could still be a reality, says Novo Nordisk

Andrew McConaghie 2017ADA, ADA 2017, insulin, Novo Nordisk 0 Comment

Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to

X

Oral insulin could still be a reality, says Novo Nordisk

https://pharmaphorum.com/news/oral-insulin-still-reality-says-novo-nordisk/

Red Blood Cells

Digital and Social Media/ News

Insulet has a challenger for Medtronic on the Horizon

Marco Ricci ADA 2017, artificial pancreas, Diabetes, digital health, Insulet, Omnipod Horizon, type 1 diabetes 0 Comment

System proven effective in children and adolescents as well as adults.

X

Insulet has a challenger for Medtronic on the Horizon

https://pharmaphorum.com/news/positive-data-omnipod-horizon/

minimed-670g

Articles/ Views and analysis

No overnight cure for type 1 diabetes – but closed loops offer respite

Richard Staines 2017ADA, ADA 2017, JDRF, Medtronic, type 1 diabetes 0 Comment

But still little progress on finding preventive treatments.

X

No overnight cure for type 1 diabetes – but closed loops offer respite

https://pharmaphorum.com/views-and-analysis/closed-loop-hope-t1d-management/

J&J

J&J diabetes drug hit by amputation risk

Richard Staines ADA 2017, cardiology, Diabetes, Johnson & Johnson, R&D, safety 0 Comment

Invokana produces modest CV benefit, but doubles risk of amputation

X

J&J diabetes drug hit by amputation risk

https://pharmaphorum.com/news/canvas-gives-unwanted-surprise-amputation-risk/

Diabetes finger prick

Merck, Pfizer covering bases with SGLT2 inhibitor latecomer

Richard Staines 2017ADA, ADA 2017, Diabetes, Janssen, Merck, Pfizer 0 Comment

This year’s American Diabetes Association conference takes place right next to San Diego’s baseball stadium – and like

X

Merck, Pfizer covering bases with SGLT2 inhibitor latecomer

https://pharmaphorum.com/news/merck-pfizer-cover-bases-sglt2-inhibitor/

repatha

Sanofi/Regeneron PCSK9 lowers cholesterol in diabetes patients

Richard Staines 2017ADA, ADA 2017, ADA2017, Amgen, cardiovascular, Diabetes, Regeneron, Sanofi 0 Comment

Companies awaiting CV outcomes trial, and court decision in patent case

X

Sanofi/Regeneron PCSK9 lowers cholesterol in diabetes patients

https://pharmaphorum.com/news/sanofiregeneron-pcsk9/

tweetsnip

Diabetes/ Diabetes/ News/ US

ADA to re-evaluate tweet ban after backlash

Richard Staines 2017ADA, ADA 2017, ADA2017, Diabetes, legislation, R&D 0 Comment

ADA says photo ban is to protect intellectual property.

X

ADA to re-evaluate tweet ban after backlash

https://pharmaphorum.com/news/ada-re-evaluate-tweet-ban-backlash/

Capitol Hill

Senate could back Trump health law by 4th July, despite warnings of patient impact

Richard Staines 2017ADA, ADA 2017, ADA2017, cancer, Diabetes, Donald Trump, legislation 0 Comment

Reforms could take away health insurance from 23 million, and deny insurance to those with pre-existing conditions, such as diabetes

X

Senate could back Trump health law by 4th July, despite warnings of patient impact

https://pharmaphorum.com/news/senate-approve-health-reforms-4th-july/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com